RIPK3 Inhibitor; GSK872 1X10MG

Biochem/physiol Actions

Reversible: yes

Primary TargetRIP3 Kinase

Cell permeable: yes

General description

A cell-permeable quinolinyl-benzothiazolamine compound that is reported to act as a RIP3-selective kinase inhibitor with >1,000-fold selectivity over a vast majority of more than 300 other kinases, including RIP1. RIP1 inhibitor Nec-1 (30 µM; Cat. Nos. 480065 & 505224) and genetic knockdown can be employed in conjunction with GSK′872 (3 µM) in delineating RIP1- vs. RIP3-dependency in Toll-like receptors- (TLRs) mediated necrosis and TNFR1-initiated necroptosis in the presence or absence of caspase inhibitor Z-VAD-FMK (25 µM; Cat. Nos. 627609 & 627610). While RIP3 and its downstream substrate MLKL are shown to mediate TLR3-initiated necrosis in the presence of Z-VAD-FMK in murine macrophage (BMDM & J774), fibroblast (3T3-SA & MEF), and endothelial (SVEC4-10) cultures, only in BMDM & J774 macrophage cultures is RIP1 involvement also seen in TLR3-mediated necrosis.

A cell-permeable quinolinyl-benzothiazolamine compound that is reported to act as a RIP3-selective kinase inhibitor with >1,000-fold selectivity over a vast majority of more than 300 other kinases, including RIP1. RIP1 inhibitor Nec-1 (30 µM; Cat. Nos. 480065 & 505224) can be employed in conjunction with GSK′872 (3 µM) in delineating RIP1- vs. RIP3-dependency in Toll-like receptors- (TLRs) mediated necrosis and TNFR1-initiated necroptosis in the presence or absence of caspase inhibitor Z-VAD-FMK (25 µM; Cat. Nos. 627609 & 627610).

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Kaiser, W.J., et al. 2013. J. Biol. Chem.288, 31268.

Packaging

Packaged under inert gas

10 mg in Glass bottle

Reconstitution

Following reconstitution, aliquot and freeze 9-20°C). Stock solutions are stable for up to 3 months at -20°C.

Warning

Toxicity: Standard Handling (A)